Xeris Biopharma Holdings, Inc. Revenue 2020–2025
Xeris Biopharma Holdings, Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Xeris Biopharma Holdings, Inc. revenue for the quarter ending March 31, 2026 was 83.1 M, a 38.27% increase year-over-year.
- Xeris Biopharma Holdings, Inc. revenue for the twelve months ending March 31, 2026 was 289.2 M, a 51.16% increase year-over-year.
- Xeris Biopharma Holdings, Inc. annual revenue for 2025 was 291.8 M, a 43.72% increase from 2024.
- Xeris Biopharma Holdings, Inc. annual revenue for 2024 was 203.1 M, a 23.89% increase from 2023.
- Xeris Biopharma Holdings, Inc. annual revenue for 2023 was 163.9 M, a 48.68% increase from 2022.
- Xeris Biopharma Holdings, Inc. annual revenue for 2022 was 110.2 M.
Xeris Biopharma Holdings, Inc. (XERS) — Frequently Asked Questions
Xeris Biopharma Holdings, Inc. (XERS) is a publicly traded US company. It has a market capitalization of $1.16B. In fiscal 2025 it reported revenue of $292M and net income of $554,000. Explore XERS's stock price, financial statements, earnings history, margins and key ratios below.
What is Xeris Biopharma Holdings, Inc.'s market cap?
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.16B.
What is the XERS stock price?
XERS trades at $6.71 (+3.23% on the day).
How much revenue does Xeris Biopharma Holdings, Inc. make?
Xeris Biopharma Holdings, Inc. reported revenue of $292M in fiscal 2025.
Is XERS profitable?
In fiscal 2025, Xeris Biopharma Holdings, Inc. reported net income of $554,000.